CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer.
<h4>Background</h4>A wealth of evidence obtained using mouse models indicates that CD4(+)CD25(+)FOXP3(+) regulatory T cells (Treg) maintain peripheral tolerance to self-antigens and also inhibit anti-tumor immune responses. To date there is limited information about CD4(+) T cell respons...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2006-12-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0000129&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850182991493464064 |
|---|---|
| author | Sarah L Clarke Gareth J Betts Andrea Plant Kate L Wright Tariq M El-Shanawany Richard Harrop Jared Torkington Brian I Rees Geraint T Williams Awen M Gallimore Andrew J Godkin |
| author_facet | Sarah L Clarke Gareth J Betts Andrea Plant Kate L Wright Tariq M El-Shanawany Richard Harrop Jared Torkington Brian I Rees Geraint T Williams Awen M Gallimore Andrew J Godkin |
| author_sort | Sarah L Clarke |
| collection | DOAJ |
| description | <h4>Background</h4>A wealth of evidence obtained using mouse models indicates that CD4(+)CD25(+)FOXP3(+) regulatory T cells (Treg) maintain peripheral tolerance to self-antigens and also inhibit anti-tumor immune responses. To date there is limited information about CD4(+) T cell responses in patients with colorectal cancer (CRC). We set out to measure T cell responses to a tumor-associated antigen and examine whether Treg impinge on those anti-tumor immune responses in CRC patients.<h4>Methodology and principal findings</h4>Treg were identified and characterized as CD4(+)CD25(+)FOXP3(+) using flow cytometry. An increased frequency of Treg was demonstrated in both peripheral blood and mesenteric lymph nodes of patients with colorectal cancer (CRC) compared with either healthy controls or patients with inflammatory bowel disease (IBD). Depletion of Treg from peripheral blood mononuclear cells (PBMC) of CRC patients unmasked CD4(+) T cell responses, as observed by IFNgamma release, to the tumor associated antigen 5T4, whereas no effect was observed in a healthy age-matched control group.<h4>Conclusions/significance</h4>Collectively, these data demonstrate that Treg capable of inhibiting tumor associated antigen-specific immune responses are enriched in patients with CRC. These results support a rationale for manipulating Treg to enhance cancer immunotherapy. |
| format | Article |
| id | doaj-art-4895a4b8551a4cf1b3dcf51118aa6cb2 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2006-12-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-4895a4b8551a4cf1b3dcf51118aa6cb22025-08-20T02:17:28ZengPublic Library of Science (PLoS)PLoS ONE1932-62032006-12-011e12910.1371/journal.pone.0000129CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer.Sarah L ClarkeGareth J BettsAndrea PlantKate L WrightTariq M El-ShanawanyRichard HarropJared TorkingtonBrian I ReesGeraint T WilliamsAwen M GallimoreAndrew J Godkin<h4>Background</h4>A wealth of evidence obtained using mouse models indicates that CD4(+)CD25(+)FOXP3(+) regulatory T cells (Treg) maintain peripheral tolerance to self-antigens and also inhibit anti-tumor immune responses. To date there is limited information about CD4(+) T cell responses in patients with colorectal cancer (CRC). We set out to measure T cell responses to a tumor-associated antigen and examine whether Treg impinge on those anti-tumor immune responses in CRC patients.<h4>Methodology and principal findings</h4>Treg were identified and characterized as CD4(+)CD25(+)FOXP3(+) using flow cytometry. An increased frequency of Treg was demonstrated in both peripheral blood and mesenteric lymph nodes of patients with colorectal cancer (CRC) compared with either healthy controls or patients with inflammatory bowel disease (IBD). Depletion of Treg from peripheral blood mononuclear cells (PBMC) of CRC patients unmasked CD4(+) T cell responses, as observed by IFNgamma release, to the tumor associated antigen 5T4, whereas no effect was observed in a healthy age-matched control group.<h4>Conclusions/significance</h4>Collectively, these data demonstrate that Treg capable of inhibiting tumor associated antigen-specific immune responses are enriched in patients with CRC. These results support a rationale for manipulating Treg to enhance cancer immunotherapy.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0000129&type=printable |
| spellingShingle | Sarah L Clarke Gareth J Betts Andrea Plant Kate L Wright Tariq M El-Shanawany Richard Harrop Jared Torkington Brian I Rees Geraint T Williams Awen M Gallimore Andrew J Godkin CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE |
| title | CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. |
| title_full | CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. |
| title_fullStr | CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. |
| title_full_unstemmed | CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. |
| title_short | CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. |
| title_sort | cd4 cd25 foxp3 regulatory t cells suppress anti tumor immune responses in patients with colorectal cancer |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0000129&type=printable |
| work_keys_str_mv | AT sarahlclarke cd4cd25foxp3regulatorytcellssuppressantitumorimmuneresponsesinpatientswithcolorectalcancer AT garethjbetts cd4cd25foxp3regulatorytcellssuppressantitumorimmuneresponsesinpatientswithcolorectalcancer AT andreaplant cd4cd25foxp3regulatorytcellssuppressantitumorimmuneresponsesinpatientswithcolorectalcancer AT katelwright cd4cd25foxp3regulatorytcellssuppressantitumorimmuneresponsesinpatientswithcolorectalcancer AT tariqmelshanawany cd4cd25foxp3regulatorytcellssuppressantitumorimmuneresponsesinpatientswithcolorectalcancer AT richardharrop cd4cd25foxp3regulatorytcellssuppressantitumorimmuneresponsesinpatientswithcolorectalcancer AT jaredtorkington cd4cd25foxp3regulatorytcellssuppressantitumorimmuneresponsesinpatientswithcolorectalcancer AT brianirees cd4cd25foxp3regulatorytcellssuppressantitumorimmuneresponsesinpatientswithcolorectalcancer AT gerainttwilliams cd4cd25foxp3regulatorytcellssuppressantitumorimmuneresponsesinpatientswithcolorectalcancer AT awenmgallimore cd4cd25foxp3regulatorytcellssuppressantitumorimmuneresponsesinpatientswithcolorectalcancer AT andrewjgodkin cd4cd25foxp3regulatorytcellssuppressantitumorimmuneresponsesinpatientswithcolorectalcancer |